Metoclopramide as a painkiller for intense migraine headache in emergency departments;Metoclopramida como analgésico en la cefalea migrañosa intensa en urgencias

Revista de Neurologia

Volumn 47, Issue 10, 2008, Pages 506-508

  Salazar Tortolero, Gabriel ^a,c   Huertas Campistol, A ^b   Vergez Pinto, L ^b   Ramos Brunet, A ^b   Lluch Lopez J ^a  

^a Hospital de Igualada   (Spain)

^b Departamento Maternoinfantil   (Spain)

^c NONE   (Spain)

Author keywords

Emergency department; Metoclopramide; Migraine

Indexed keywords

ANALGESIC AGENT; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TRIPTAN DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DRUG EFFICACY; EMERGENCY CARE; FEMALE; HEADACHE; HUMAN; MALE; MIGRAINE; PAIN; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 57049151341     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4710.2008294     Document Type: Article

References (23)

1. Holroyd KA, Drew JB, Cottrell CK, Romanek KM, Heh V. Impaired functioning and quality of life in severe migraine: the role of catastrophizing and associated symptoms. Cephalalgia 2007; 27: 1156-65.
2. Gerth WC, Carides GW, Dasbach EJ, Visser WH, Santanello NC. The multinational impact of migraine symptoms on healthcare utilisation and work loss. Pharmacoeconomics 2001; 19: 197-206.
3. Volcy-Gómez M. Impacto social, económico y en el sistema de salud de la migraña y otras cefaleas primarias. Rev Neurol 2006; 43: 228-35.
4. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2: 67-76.
5. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343-9.
6. Badía X, Magaz S, Gutiérrez L, Galván J. The burden of migraine in Spain: beyond direct costs. Pharmacoeconomics 2004; 22: 591-603.
7. Pascual J, Mateos V, Roig C, Sánchez-Del Río M, Jiménez D. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. Headache 2007; 47: 1152-68.
8. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633-58.
9. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S; American Academy of Neurology Quality Standards Subcommittee; Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004; 63: 2215-24.
10. Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología. Tratamiento de las cefaleas primarias y algias faciales. Recomendaciones 2006. URL: http://cefaleas.sen.es/profesionales/rec2006/ anexo_II.pdf. [12.04.2008].
11. Johnson MP, Fernández F, Colson NJ, Griffiths LR. A pharmacogenomic evaluation of migraine therapy. Expert Opin Pharmacother 2007; 8: 1821-35.
12. Mateos V, Galván J, Heras J. Estrategias terapéuticas utilizadas por neurólogos y médicos de atención primaria en el tratamiento sintomático de la migraña. Resultados de los estudios de opinión Strategia-I y Strategia-II. Rev Neurol 2006; 43: 513-7.
13. Granella F, Alessandro R, Manzoni G, Cerbo R, Colucci C, Pini L. International Headache Society classification: interobserver reliability in the diagnosis of primary headaches. Cephalalgia 1994; 14: 16-20.
14. Agosti RM. 5HT1F- and 5HT7-receptor agonists for the treatment of migraines. CNS Neurol Disord Drug Targets 2007; 6: 235-7.
15. Fanciullacci M, Alessandri M, Del Rosso A. Dopamine involvement in the migraine attack. Funct Neurol 2000; 15 (Suppl 3): S171-81.
16. Hoffmann J, Reuter U. Treatment of migraine. Dtsch Med Wochenschr 2007; 132: 2153-8.
17. Loder EW. Review: intravenous metoclopramide is better than placebo for reducing pain in acute migraine in the emergency department. ACP J Club 2005; 142: 77.
18. Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache 2006; 46: 781-71.
19. Allena M, Magis D, Schoenen J. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005; 64: 463-8.
20. Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. ACP J Club 2005; 142: 77.
21. Friedman BW, Corbo J, Lipton RB, Bijur PE. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005; 64: 463-8.
22. Hakkarainen H, Allonen H. Ergotamine vs. metoclopramide vs. their combination in acute migraine attacks. Headache 1982; 22: 10-2.
23. Parlak I, Erdur B, Parlak M, Ergin A, Turkcuer I, Tomruk O, et al. Intravenous administration of metoclopramide by 2 min bolus vs 15 min infusion: does it affect the improvement of headache while reducing the side effects? Postgrad Med J 2007; 83: 664-8.